- Timo grimmer is in the team - All endpoints of the clinical trial were reached I firmly believe that the drug works and that the CEO has done a good job no matter how much he is criticized.

The drug shows it works as is!

we have a drug, even many drugs, good for so many indications, to become a giant pharma, we are about to get billions in revenues.

$AVXL The improvements in the drug arm cannot be lucky. .

Our drug has no side effects.

I'm looking forward to seeing the long term AD data on ANVS and have the feeling it's going to end up being the best in class AD treatment as well.

Do not listen to any FUD this drug is the real deal.

$AVXL amazing to see the actual benefits to people and their families of this “miracle drug” as they call it

$AVXL Dr. Perry said we have a legendary drug which actually reverses AD and is safe unlike Adulhelm.

Still Bull, still confident its a great drug.

$AUPH Since VOC is the only drug with any evidence classified as “High”, this stock will definitely be acquired above $30+++!!!

Blockbuster drug with improving sales and long patent life

BP would save so many lives with this drug.

1 Its approved and works great 2 Cause I see value.. IE BO GRABS 🍿

The ability to spread the drug’s benefits and get patients aware of the treatment would put us in a spotlight that no other way could.

• 97% gross margin (sheesh) • Excited bout new partnership(details soon) • drug price increase • 85% conversion psf's (stellar) • Tam is there, huge growth opportunity if they can get more sle patients tested, 75% would capture many.

LUPKYNIS is undoubtedly the best-in-class drug to treat Lupus Nephritis.

Before people start complaining about voc pricing, it’s cheaper than my drug, and life saving, whereas mine is joint sparing… What’s the bear thesis here again? ?

I have concluded SLS are developing the best in a class of immunotherapy drug.

This drug has no serious toxicity issues and extends OAs.

$MRK Ovarian cancer data final P2 results are better than any other drugs by a mile.

They have the best in class "CDK9 inhibitor" (if that drug class even exists.

Be Holding as many as you can - the announcement will be coming any day from here on out and its worth an instant billion plus in Market value - Treating 20,000 patients each year, market comp drug pricing at $250K per.